Dexamethason for the treatment of exacerbations in multiple sclerosis

Department of Neurology UMCG0 个研究点目标入组 60 人开始时间: 2006年7月21日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1) patients with multiple sclerosis (MS), diagnosed according to the MacDonald criteria with a relapsing-remitting or secundary progressieve subtype.
•2) age 18 - 65 yrs, male or female
•3) patients have to be experiencing an exacrebation. Exacerbation is defined as the development of a new symptom or the worsening of an established symptoms of MS of a duration of more than 24 hours and in the absence of fever or other disease
•4) The exacerbation must encompass at least one of the following symptoms: arm or leg paresis, gait problems because of paresis or ataxia, limb ataxia, sensory loss, optic neurtitis, diplopia
•5) The exacerbation is present for no more than seven days at randomisation
•6) Informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1) Use of corticosteroids in the previous three months
•2) Contraindication for coritcosteroid-use (psychosis, active peptic ulcer, infection etc.)
•3) Circumstanced in which constant medical monitoring is required ( e.g. diabetes mellitus)
•4) Pregancy and breast-feeding
•5) A MS-relapse in the previous eight weeks

发起方

Department of Neurology UMCG